AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Newsfilter
Partnership Expansion: AccuStem Sciences and EmeritusDX are expanding their partnership to commercialize the MSC test for lung cancer screening, which analyzes microRNAs to improve lung nodule stratification and patient outcomes.
Future Plans: The MSC test is set to launch in US clinics in 2026, with both companies working on reimbursement strategies to increase access for the 1.6 million patients diagnosed with lung nodules annually.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
